" class="no-js "lang="en-US"> SeaBeLife - Medtech Alert
Thursday, September 04, 2025
SeaBeLife | Pharmtech Focus

SeaBeLife

About SeaBeLife

SeaBeLife
SeaBeLife is a biotechnology company that is currently developing families of patented candidate molecules designed to block regulated necrosis (that is, regulated cell death). SeaBeLife technology has been demonstrated in vitro and in several proofs-of-concept in vivo, to be able to simultaneously block two forms of regulated cell death and thus to protect organs under attack from disease.

Related Story

Seabelife Receives Close to €1.4m Deep Tech Financing from Bpifrance

March 14 2022

SeaBeLife, a biotech company developing drug candidates intended to block cell necrosis, today announces that […]